These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 29945964)

  • 1. Enhanced Glycolysis Supports Cell Survival in EGFR-Mutant Lung Adenocarcinoma by Inhibiting Autophagy-Mediated EGFR Degradation.
    Kim JH; Nam B; Choi YJ; Kim SY; Lee JE; Sung KJ; Kim WS; Choi CM; Chang EJ; Koh JS; Song JS; Yoon S; Lee JC; Rho JK; Son J
    Cancer Res; 2018 Aug; 78(16):4482-4496. PubMed ID: 29945964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upregulation of E3 Ubiquitin Ligase CBLC Enhances EGFR Dysregulation and Signaling in Lung Adenocarcinoma.
    Hong SY; Kao YR; Lee TC; Wu CW
    Cancer Res; 2018 Sep; 78(17):4984-4996. PubMed ID: 29945960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blocking autophagy improves the anti-tumor activity of afatinib in lung adenocarcinoma with activating EGFR mutations in vitro and in vivo.
    Hu X; Shi S; Wang H; Yu X; Wang Q; Jiang S; Ju D; Ye L; Feng M
    Sci Rep; 2017 Jul; 7(1):4559. PubMed ID: 28676644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of pyruvate dehydrogenase kinase 1 enhances the anti-cancer effect of EGFR tyrosine kinase inhibitors in non-small cell lung cancer.
    Yang Z; Zhang SL; Hu X; Tam KY
    Eur J Pharmacol; 2018 Nov; 838():41-52. PubMed ID: 30213498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erlotinib-induced autophagy in epidermal growth factor receptor mutated non-small cell lung cancer.
    Li YY; Lam SK; Mak JC; Zheng CY; Ho JC
    Lung Cancer; 2013 Sep; 81(3):354-361. PubMed ID: 23769318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reactivation of Mutant-EGFR Degradation through Clathrin Inhibition Overcomes Resistance to EGFR Tyrosine Kinase Inhibitors.
    Ménard L; Floc'h N; Martin MJ; Cross DAE
    Cancer Res; 2018 Jun; 78(12):3267-3279. PubMed ID: 29555874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
    Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
    Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors.
    Juchum M; Günther M; Laufer SA
    Drug Resist Updat; 2015 May; 20():12-28. PubMed ID: 26021435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of the Aryl Hydrocarbon Receptor Leads to Resistance to EGFR TKIs in Non-Small Cell Lung Cancer by Activating Src-mediated Bypass Signaling.
    Ye M; Zhang Y; Gao H; Xu Y; Jing P; Wu J; Zhang X; Xiong J; Dong C; Yao L; Zhang J; Zhang J
    Clin Cancer Res; 2018 Mar; 24(5):1227-1239. PubMed ID: 29229632
    [No Abstract]   [Full Text] [Related]  

  • 10. BIX01294 inhibits EGFR signaling in EGFR-mutant lung adenocarcinoma cells through a BCKDHA-mediated reduction in the EGFR level.
    Kim JH; Kim J; Im SS; Lee JH; Hwang S; Chang EJ; Shin DM; Rho JK; Son J
    Exp Mol Med; 2021 Dec; 53(12):1877-1887. PubMed ID: 34876693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD44 variant-dependent regulation of redox balance in EGFR mutation-positive non-small cell lung cancer: A target for treatment.
    Kawano Y; Iwama E; Tsuchihashi K; Shibahara D; Harada T; Tanaka K; Nagano O; Saya H; Nakanishi Y; Okamoto I
    Lung Cancer; 2017 Nov; 113():72-78. PubMed ID: 29110853
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.
    Lin C; Chen X; Li M; Liu J; Qi X; Yang W; Zhang H; Cai Z; Dai Y; Ouyang X
    Clin Lung Cancer; 2015 Sep; 16(5):e25-35. PubMed ID: 25801750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different subtypes of EGFR exon19 mutation can affect prognosis of patients with non-small cell lung adenocarcinoma.
    Tian Y; Zhao J; Ren P; Wang B; Zhao C; Shi C; Wei B; Ma J; Guo Y
    PLoS One; 2018; 13(11):e0201682. PubMed ID: 30383772
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual effects of a CpG-DNAzyme targeting mutant EGFR transcripts in lung cancer cells: TLR9 activation and EGFR downregulation.
    Jang D; Baek YM; Park H; Hwang YE; Kim DE
    BMB Rep; 2018 Jan; 51(1):27-32. PubMed ID: 28893372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
    Zhou J; Kwak KJ; Wu Z; Yang D; Li J; Chang M; Song Y; Zeng H; Lee LJ; Hu J; Bai C
    Cell Physiol Biochem; 2018; 47(5):1909-1924. PubMed ID: 29961070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic cell growth inhibition by the combination of amrubicin and Akt-suppressing agents in K-ras mutation-harboring lung adenocarcinoma cells: implication of EGFR tyrosine kinase inhibitors.
    Ito S; Igishi T; Takata M; Ueda Y; Matsumoto S; Kodani M; Takeda K; Izumi H; Sakamoto T; Yamaguchi K; Makino H; Touge H; Chikumi H; Shimizu E
    Int J Oncol; 2014 Mar; 44(3):685-92. PubMed ID: 24399305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Selective and Potent EGFR Inhibitor that Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer.
    Li Y; Song Z; Jin Y; Tang Z; Kang J; Ma X
    Molecules; 2016 Nov; 21(11):. PubMed ID: 27827863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional cooperation between HIF-1α and c-Jun in mediating primary and acquired resistance to gefitinib in NSCLC cells with activating mutation of EGFR.
    Meng S; Wang G; Lu Y; Fan Z
    Lung Cancer; 2018 Jul; 121():82-90. PubMed ID: 29858032
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.
    Stewart EL; Mascaux C; Pham NA; Sakashita S; Sykes J; Kim L; Yanagawa N; Allo G; Ishizawa K; Wang D; Zhu CQ; Li M; Ng C; Liu N; Pintilie M; Martin P; John T; Jurisica I; Leighl NB; Neel BG; Waddell TK; Shepherd FA; Liu G; Tsao MS
    J Clin Oncol; 2015 Aug; 33(22):2472-80. PubMed ID: 26124487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urea Cycle Sustains Cellular Energetics upon EGFR Inhibition in EGFR-Mutant NSCLC.
    Pham-Danis C; Gehrke S; Danis E; Rozhok AI; Daniels MW; Gao D; Collins C; Paola JTD; D'Alessandro A; DeGregori J
    Mol Cancer Res; 2019 Jun; 17(6):1351-1364. PubMed ID: 30808730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.